Impact Factor 4.416
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Oncol. | doi: 10.3389/fonc.2019.00114

Diagnostic Significance of Serum IgG Galactosylation in CA19-9-negative Pancreatic Carcinoma Patients

Ailing Zhong1, Ruihuan Qin1, Wenjun Qin1, Jing Han1, Yong Gu1, Lei Zhou1, Hongqin Zhang1,  Shifang Ren1*,  Renquan Lu1*, Lin Guo1 and  Jianxin Gu1
  • 1Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, China

Although Carbohydrate antigen 19-9 (CA19-9) is considered clinically useful and informative for pancreatic carcinoma (PC), false positive results and false negative results have restricted its clinical use. Especially missed or delayed diagnosis of PC patients with negative CA19-9 value is limited the utility. To improve prognosis of PC patients, the discovery of reliable biomarkers to assist CA19-9 is desired. Serum IgG galactosylation based on our previous report was altered in PC patients comparing to healthy controls. The objective of this study was to explore the diagnositic significance of IgG galactosylation in assisting CA19-9 for PC in a comprehensive way.
Serum IgG galactosylation profiles were analyzed by MALDI MS in cohort 1 (n=237) and cohort 2 in which all CA19-9 levels were negative (n=124). In each cohort, not only healthy controls and PC patients but also benign pancreatic cysts (BPC) patients were enrolled. Peaks were acquired by the software of MALDI-MS sample acquisition, followed by being processed and analyzed by the software of Progenesis MALDI. IgG Gal-ratio, which was calculated from the relative intensity of peaks G0, G1 and G2 according to the formula (G0/(G1+G2×2)), was employed as an index for indicating the distribution of IgG galactosylation.
The Gal-ratio was elevated in PC than in healthy controls and BPC (p < 0.001). The area under the receiver operating characteristic curve (AUC) of IgG Gal-ratio was higher than that of CA19-9 (0.934 vs 0.819). The performance was further improved when Gal-ratio and CA19-9 were combined (AUC: 0.947). Meanwhile, Gal-ratio also had great diagnostic value with a sensitivity of 95.00% (AUC: 0.924) in detection of PC at early stage. Notably, IgG Gal-ratio has great sensitivity (90.63%) and specificity (78.33%) in CA19-9-negative PC patients.
IgG Gal-ratio had a great performance in detection of PC and could be used to assist CA19-9 in improving diagnosis performance through early stage detection, differentiation from BPC, and PC diagnosis with CA19-9-negative level.

Keywords: Pancreatic carcinoma, IgG, galactosylation, Diagnostic biomarker, CA19-9

Received: 09 Jul 2018; Accepted: 07 Feb 2019.

Edited by:

Ulf P. Neumann, Faculty of Medicine, RWTH Aachen University, Germany

Reviewed by:

Hakan Alagozlu, University of Istinye, Turkey
Cornelis F. Sier, Leiden University, Netherlands  

Copyright: © 2019 Zhong, Qin, Qin, Han, Gu, Zhou, Zhang, Ren, Lu, Guo and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Prof. Shifang Ren, Fudan University, Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai, China, renshifang@fudan.edu.cn
Prof. Renquan Lu, Fudan University, Key Laboratory of Glycoconjugate Research Ministry of Public Health, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai, China, lurenquan@126.com